Answer
Cabaser (cabergoline) is second-line therapy for Parkinson’s symptoms when non-ergot treatment fails or is not tolerated, used alone or alongside levodopa plus a dopa-decarboxylase inhibitor, initiated under specialist supervision, with continued benefit regularly reassessed against fibrosis and valvulopathy risks.
Sources for this answer
- Cabaser 1 mg TabletsPfizer Limited · emc · SmPC §4.1 Therapeutic Indications · Version 11Document updated
Sources checked